"In 2021, we started collecting data on opioids prescribed at discharge to see whether or not patients did or did not get prescribed opioids," says Katherine Wang, MD.
In this video, Katherine Wang, MD, discusses the background behind the Urology Practice study “Practice-Level Variation in Opioid-Free Discharge Following Surgery for T1 Renal Masses: A MUSIC-KIDNEY Analysis.” Wang is a research fellow in the department of urology at Henry Ford Health System in Detroit, Michigan.
In the [p]ast 10 to 20 years, there's [been] an ongoing opioid epidemic. I'm sure you know about it, as a lot of people do. And unfortunately, physicians are actually one of the contributing factors, especially with surgical subspecialties. After surgery, we tend to prescribe patients some opioids after discharge just to deal with pain and try to mitigate that. But unfortunately, there are no set prescribing patterns. And we tend to over-prescribe opioids. And so we decided to look at this in Michigan through our collaborative called MUSIC, the Michigan Urological Surgery Improvement Collaborative, which is a quality improvement collaborative here just to see if there were any implications with opioid-free discharge, whether that's safe or feasible for kidney cancer surgery. Our collaborative MUSIC has a branch called MUSIC-KIDNEY, which collects data on T1 renal masses, which is kidney cancer masses smaller than 7 cm. In 2021, we started collecting data on opioids prescribed at discharge to see whether or not patients did or did not get prescribed opioids. And so in this setting, we evaluated the safety and feasibility of opioid-free discharge after kidney cancer surgery.
This transcription was edited for clarity.
Adding nivolumab to low-dose tivozanib does not improve PFS in renal cell carcinoma
July 19th 2024"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.
Live bacterial supplementation may improve TKI-based treatment efficacy in kidney cancer
June 30th 2024CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes, and modulate the gut microbiota in beneficial ways,” says Sumanta Pal, MD.
Pembrolizumab/lenvatinib labels updated to include KEYNOTE-B61 data in non-ccRCC
June 28th 2024"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.